Keep containers securely sealed when not in use. Glass, polyethylene or polypropylene containers. Check all containers are clearly labeled and free from leaks. Store in impervious break-resistant containers. Should be stored in separate, clearly marked storage areas to minimize the risk of breakage, and to limit contamination in the event of leakage.

IATA: Hazard Class: 9; Un No: UN3077; Packing Group: III; Shipping Name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (CONTAINS GEFITINIB)

Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 304(5676):1497-1500.

Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies suggest that Gefitinib can enhance keratinocyte apoptosis via an EGFR-independent JNK-activation pathway. Research indicates that Gefitinib can induce apoptosis in several cell lines including, HaCaT cells, KG-1, P39, and primary CD34+ myeloblasts. Erlotinib has similar properties to Gefitinib